Science
Rethinking the role of pathogenic drivers in rheumatoid arthritis
December 16, 2019      Updated: August 20, 2024
Sheila Kelly, MD, Global Program Lead, Late Development Immunology

Rheumatologists are all too familiar with the significant impact rheumatoid arthritis (RA), a destructive, immune-mediated disease, can have on patients. In RA, the body’s immune system quite literally attacks its own joints, causing pain, stiffness and swelling in areas such as the hands, wrists and knees. But, more and more, the community’s collective knowledge of pathogenic drivers and the underlying mechanism of disease continues to evolve, offering physicians and patients the opportunity to rethink approaches to RA. Additionally, research is exploring a potential role for pathogenic drivers in treatment selection in RA.

Reviewing the pathogenesis of RA: Who are the key players?

Two pathways play a role in RA: B-cell-derived autoantibodies, such as rheumatoid factors (RF) and anti-citrullinated protein autoantibodies (ACPA); and proinflammatory cytokines, including IL-1, IL-6, IL-8, and TNF-α. Production of both drivers is dependent on T-cell activation. While the impact of proinflammatory cytokines in RA is well known, recent research has deepened our understanding of the role of RF and ACPA. Because they can be present years before an RA diagnosis, and may lead to worse outcomes, such as joint damage, these autoantibodies can be important diagnostic and prognostic biomarkers for physicians to understand and consider.

Rethinking the autoimmune cycle: What drives RA progression?

Once formed, autoantibodies and proinflammatory cytokines become effector molecules that drive destructive autoimmune disease pathology through feedback loops. The eventual activation of downstream effectors may lead to permanent structural damage, such as bone and cartilage erosion, synovitis, pain, and other joint-related abnormalities.

Currently, there are RA treatments available that target a variety of important immune players. Understanding RA initiation, progression and prognosis may aid in treatment decision-making.


Subscribe to Our stories alerts
 

Beyond just relevant information about Bristol Myers Squibb's therapeutic areas and innovation, Our stories offer a window into the work our employees do every day for patients.


About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.